Patent Grant23 May 2018 08:04
"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins. We are now well positioned to develop a pipeline of new Moditope(R) therapies with the potential to address the unmet need across a broad range of hard to treat cancers including ovarian, triple negative breast cancer and sarcoma."